I'm on the extreme end of thinking it should have been approved faster - but even if you are a bit of a traditionalist I don't see how running concurrent trials on such an important potential vaccine wouldn't be a huge win.
The trials take something like 3 months from first shot to results, I think. It took a lot more than 3 months from phase 3 completed to most people vaccinated in most Western countries and obviously much longer in developing ones.
But there is very little financial incentive to run such trials once you have a vaccine approved...
The problem is on the government side. They should have paid for this. It would have saved them money too - if it turned out they only needed to give out one shot of the mRNA doses or that they could cut down on dosage.
If you check the papers for the mRNA vaccines, you can see that they did run several different dose levels and got pretty clear feedback that some were too high or too low, before moving on to phase III.
If you read the abstract in phase II they gave it to a small amount of people and looked in detail how the immune system responded in these individuals. This is very granular data.
Phase III is more like "We have no idea what the immune system did in certain people - but only 0.1% of vaccinated people ended up in hospital compared to 2% of placebo" or whatever.
The important thing for the vaccine was too limit death and hospitalization. And phase II didn't tell us clear info on that.
What if they had found that half the dosage ended up in the same number of hospitalizations? There's no way to get that from phase II data.
> The important thing for the vaccine was too limit death and hospitalization. And phase II didn't tell us clear info on that.
Phase II is primarily to test that the "candidate is safe, sufficiently immunogenic, and maybe protective"[1]. It's not clear to me that testing hospitalization percentage is in scope.
In a very real-world sense the "optimal dose" is 100% about finding hospitalization/health data. The "optimal dose" in phase II is about the microbiology and isn't very precise in terms of how it translates to real world effects.
But while a decrease in hospitalization is important, I disagree that it's the only thing that we should be optimizing against. I'm not sure what you mean by health data, but safety and immunogenicity (which might be upstream of hospitalization) are incredibly important to consider in the choice of dosage as well, and that's what optimal dose in the context of trials means. This is the context which I meant it in, and I'm just borrowing this terminology from other places, e.g.:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4944327/ https://pubmed.ncbi.nlm.nih.gov/29420118/
Once its approved already at a set dose, the "ideal dose" for future use is probably not the same as the "optimal dose" that maximized probability of approval.
"We propose a Bayesian utility approach (BUART) to randomized Phase II clinical trials which uses a first-order bivariate normal dynamic linear model for efficacy and safety in order to determine the optimal dose and study population in a subsequent Phase III clinical trial. "
And even if they just prioritized starting the first one ASAP - they didn't do any dosage testing until after it had been released to general public for months. Even if not ideal they could have started dosage trials in November after all the data from the original was done. Instead, they waited six months before even considering this.
If somehow they're able to run trials on 12x the volunteers, I would rather that they increase the participants by 12x for the final dose so that you get more confidence in the Phase 3 study results and in finding rare side effects.
Transport, preparation and process are very operationally challenging.
Edit: ridiculous that HN community downvotes attempts to have conversation; you're part of the problem.